Allist Says FURVENT Phase III Failure Won’t Hit Fumatinib Sales

Allist's claim that the FURVENT setback leaves sales untouched rests on a narrow base: revenue is tied to first-line EGFR-sensitizing mutations, not the overseas indication that failed. That distinction matters because it separates near-term commercial exposure from the longer-term pipeline question the Phase III result raises. The open question is whether the company's follow-up development and regulatory plans, pending further data analysis, eventually force a reassessment of fumatinib's growth story beyond its current label.